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Abstract 
Objective.  The clinical importance of preoperative CYFRA 21-1 measurement in early stage 
non-small cell lung cancer (NSCLC) is still unclear.  The aim of this study is to clarify the 
prognostic value of preoperative CYFRA 21-1 levels in clinical stage (c-stage) I NSCLC. 
Methods.  The records of 101 c-stage I NSCLC patients who had undergone complete resection 
were analyzed to correlate preoperative CYFRA 21-1 levels to both the pathologic factors of 
resected specimens and postoperative outcomes.  The cut-off value was set at 3.5 ng/mL. 
Results.  Six cases (5.9%) showed high CYFRA 21-1 (≥3.5 ng/ml).  The 5-year survival of 
normal and high CYFRA 21-1 groups were 83.3% and 50.0%, respectively.  Patients with high 
CYFRA 21-1 had significantly poor outcomes (P=0.006).  In univariate analysis, preoperative 
serum CYFRA 21-1 level, pT, pN and p-stage were significantly associated with prognosis.  
Multivariate analysis showed that only CYFRA 21-1 level retained as an independent prognostic 
factor (relative risk=9.79, P=0.002). 
Conclusions.  CYFRA 21-1 is an independent predictor of poor outcome for c-stage I NSCLC.  
Elevated preoperative CYFRA 21-1 levels in early stage NSCLC may indicate a subgroup at high 
risk of early death, which has the potential for better survival with additional systemic 
chemotherapy. (196 words)  
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Introduction 
Cytokeratin 19 is expressed in simple epithelium such as bronchial epithelium and is particularly 
abundant in carcinoma of the lung [1].  A fragment of cytokeratin 19, CYFRA 21-1 can be 
measured in serum by an immunoradiometric assay using two mouse monoclonal antibodies KS 
19-1 and BM 19-21 [2].  The CYFRA 21-1 serum level has been reported and accepted as a useful 
tumor marker in patients with non-small cell lung cancer (NSCLC) [2-6].  However, the clinical 
importance of CYFRA 21-1 level in early lung cancer is not clear.  Meanwhile, the prognosis for 
early stage NSCLC patients who undergo curative operations remains unsatisfactory, as the 5-year 
postoperative survival rate is about 70% even in c-stage IA [7].  Therefore, it would be beneficial 
to identify some preoperative factors which could help with the prognosis of early stage patients.  
This study was performed to clarify the prognostic value of preoperative CYFRA 21-1 levels in 
completely resected c-stage I NSCLC patients. 
 
Materials and Methods 
Patients 
Between August 1994 and May 2001, 309 consecutive primary NSCLC patients underwent 
surgical resection after measurement of serum CYFRA 21-1 at the Department of Thoracic Surgery, 
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Tsukuba University Hospital, Japan.  Of these patients, 101 cases diagnosed as c-stage I were 
analyzed in this study, and all cases had formal lobectomy with systemic lymphadenectomy and no 
induction chemotherapy.  The characteristics of the 101 patients included in the study are shown in 
Table 1.  The study population consisted of 61 male and 40 female patients.  The median age was 
67 years (ranging from 33 to 81 years).  Surgical procedures consisted of lobectomy in 97 patients 
and bilobectomy in 4 patients.  The study protocol was approved by the Institutional Review 
Board of University of Tsukuba. 
 
TNM Evaluation and Histology 
The staging of each case was determined according to the TNM classification of the revised 
International System for the Staging of Lung Cancer [8] and the histological classification of the 
tumors was based on the World Health Organization’s criteria [9].  All patients were preoperatively 
diagnosed as T1-2N0 status by chest computer assisted tomography (CT) and as M0 by abdominal 
ultrasonography, brain CT or magnetic resonance imaging, and bone scintigraphy.  After 
pathological examination of resected surgical specimens, 66 patients were categorized as pT1 and 
20 as pT2.  Seven patients were diagnosed as pT3 because of tumor invasion to the chest wall or 
mediastinal pleura and 8 were diagnosed as pT4 because of satellite tumor nodules within the 
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primary tumor lobe.  Lymph node involvement was observed postoperatively in 27 patients, of 
which 17 were pN1 and 10 were pN2.  Surgical pathologic stagings (p-stage) were stage I in 65 
patients, p-stage II in 18, p-stage IIIA in 8 because of mediastinal nodal involvement, p-stage IIIB 
in 8 because of the presence of satellite nodules within the primary tumor lobe, and p-stage IV in 2 
because of the presence of pulmonary metastasis beyond the primary tumor lobe.  These metastatic 
nodules which co-existed either in the same lobe as the primary lesion or beyond it were so small 
that only histological examination of the surgical specimen revealed the lesions.  The histologic 
types of the primary lesions were mainly adenocarcinoma (n=72), as shown in Table 1. 
 
Serum Assay 
The serum levels of CYFRA 21-1 were determined using a chemiluminescent enzyme 
immunoassay (Lumipulse I CYFRA, Fujirebio Inc., Tokyo, Japan).  We used 3.5 ng/ml as the 
cut-off value of serum CYFRA 21-1, as established by the Japan CYFRA research group [10]. 
 
Statistical Analyses and Survival Rates  
Data is shown as mean ± SE.  The significance of the differences between two independent 
groups was determined by unpaired t-test, and that among more than two groups was determined by 
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analysis of variance and Tukey’s test.  The length of survival was defined as the interval in months 
between the day of surgical resection and the date of death or last follow-up visit.  The median 
follow-up for surviving patients was 73.0 months.  The survival rates were calculated by the 
Kaplan-Meier method and univariate analyses were performed by means of the log-rank test.  
Multivariate analyses were performed by means of the Cox proportional hazards model.  A 0.10 
level of probability value was the significance level used for adding and deleting a co-variable from 
the model.  All statistical analyses were performed using SPSS 10.1J for Windows (SPSS Inc., 
Chicago, IL) and a probability value less than 0.05 was considered to be significant. 
 
Results 
The CYFRA 21-1 levels for groups divided into different categories are shown in Table 2.  The 
preoperative CYFRA 21-1 level of all 101 patients was 1.66 ± 0.09 ng/ml (ranging from 0.5 to 4.3 
ng/ml).  Six out of the 101 patients (5.9%) had high CYFRA 21-1 levels.  These 6 patients with 
high CYFRA 21-1 were older than 64 years old: 5 were male and 1 was female, consisting of 1 
squamous cell carcinoma and 5 non-squamous cell carcinoma, and 5 p-stage I and 1 p-stage III 
cases.   
 
  8 
Patient Profile and CYFRA 21-1 Level 
The CYFRA 21-1 level was observed to be higher in males and in those older than 64 years old.  
The differences, however, were not statistically significant. 
 
Histology and CYFRA 21-1 Level 
As for histological types, the CYFRA 21-1 levels were 1.54 ± 0.10 ng/ml for adenocarcinoma, 
1.92 ± 0.19 ng/ml for squamous cell carcinoma, and 1.97 ± 0.41 ng/ml for large cell carcinoma.  
There were no significant differences in the CYFRA 21-1 levels among these groups.  Comparison 
of the CYFRA 21-1 levels between squamous cell carcinoma patients and the others showed an 
upward trend in this factor in the squamous cell carcinoma group (P=0.06).  
 
pTNM and CYFRA21-1 Level 
The serum levels of CYFRA 21-1 were 1.44 ± 0.10 ng/ml for pT1, 2.16 ± 0.21 ng/ml for pT2, 
1.66 ± 0.29 ng/ml for pT3, and 2.19 ± 0.37 ng/ml for pT4 patients.  A significant difference was 
found between the pT1 and pT2 groups (P=0.006).  No significant differences were observed 
between other individual groups.  The CYFRA 21-1 level for a group of pT2-4 patients was 2.06 ± 
0.16 ng/ml and the difference between the pT1 and pT2-4 groups was also significant (P<0.001).  
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Although we performed a linear regression analysis to confirm the correlation between tumor size 
and CYFRA 21-1 level, no correlation was observed (r=0.162, P=0.102).   
The CYFRA 21-1 levels were 1.69 ± 0.11 ng/ml for the pN0 patients and 1.56 ± 0.14 ng/ml for 
the pN1-2 patients.  The difference in the CYFRA 21-1 serum levels was not significant between 
the groups with and without lymph node involvement. 
The levels of CYFRA 21-1 were 1.66 ± 0.12 ng/ml for p-stage I, 1.72 ± 0.15 ng/ml for p-stage II, 
1.20 ± 0.11 ng/ml for p-stage IIIA, 2.19 ± 0.37 ng/ml for p-stage IIIB, and 0.75 ± 0.25 ng/ml for 
p-stage IV.  Among these groups, there were no significant differences in the levels of CYFRA 
21-1.  A comparison between the groups of p-stage I and of p-stages II through IV showed no 
significant differences either. 
 
CYFRA 21-1 Level and Survival 
The 3- and 5-year survival rates after surgery for all patients were 86.6% and 81.1%, respectively.  
Figure 1 shows survival curves for patients with preoperatively normal serum CYFRA 21-1 level 
and patients with preoperatively high (≥3.5 ng/ml ) serum CYFRA 21-1 level.  The 5-year survival 
rate was 84.8% for normal CYFRA 21-1 patients and 50.0% for high CYFRA 21-1 patients, and the 
difference between these two groups was statistically significant (P=0.006).  Six patients had high 
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CYFRA 21-1 levels, three of whom died of distant metastases of NSCLC, and their preoperative 
CYFRA 21-1 levels were 3.6 ng/ml with p-stage IB squamous cell carcinoma, 3.8 ng/ml with 
p-stage IB adenocarcinoma, and 4.1 ng/ml with p-stage IIIB adenocarcinoma.   
The potential prognostic factors were subjected to a univariate survival analysis (Table 3).  
CYFRA 21-1 levels (P=0.006), pT factor (P=0.019), pN factor (P=0.016), and pathological stage 
(P=0.004) were significantly associated with a worse outcome.  To determine independent 
prognostic factors, we performed multivariate analyses according to the Cox proportional hazards 
model.  Table 4 shows the results of the multivariate analyses.  The CYFRA 21-1 serum level was 
the only factor to retain a significant independent prognostic impact on overall survival (relative 
risk=9.79, P=0.002).  
 
Discussion 
The most important findings of this study are that the c-stage I NSCLC patients with preoperative 
serum levels of CYFRA 21-1 higher than 3.5 ng/ml had significantly worse outcomes after surgical 
resection and multivariate analysis showed CYFRA 21-1 to be an independent prognostic factor. 
CYFRA 21-1 is measured by a sandwich enzyme-linked immunosorbent assay developed to detect 
a soluble cytokeratin 19 fragment which is expressed in bronchial epithelium and malignant lung 
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tumors.  In 1993, Pujol et al. [2] demonstrated the reliability of this method as a new tumor marker 
for lung cancer, especially NSCLC.  Since then, many studies on the relationship between CYFRA 
21-1 levels and NSCLC have been reported, and CYFRA 21-1 is now known as a useful tumor 
marker for NSCLC with high positive rates [3-5].  Variation in CYFRA 21-1 levels among 
different histological groups in NSCLC have also been reported, showing higher sensitivities in 
squamous cell carcinoma than in adenocarcinoma [5, 11].  In regards to squamous cell carcinoma 
cases, Reinmuth et al. [5] demonstrated that CYFRA 21-1 is the marker with the highest sensitivity 
compared to other markers, such as carcinoembryonic antigen and squamous cell carcinoma-antigen.  
In our study, squamous cell carcinoma group had an upward trend of CYFRA 21-1 levels as 
compared with other histological types, although the difference was not statistically significant 
(P=0.06).  The low proportion of squamous cell carcinoma in our subjects (21/101 patients or 
20.8%) may be a reason that the difference did not reach statistical significance. 
According to the pathologic T status, we observed a significantly lower CYFRA 21-1 level in 
pT1 patients as compared to pT2 and pT2-4 patients.  Lai et al. [3] classified the patients into three 
groups according to tumor size in squamous cell carcinoma with p-stages I, II, and partial IIIA, and 
showed significantly higher serum CYFRA 21-1 levels in those with larger tumor size.  However, 
a linear regression analysis performed on our cases did not show the correlation between tumor size 
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and CYFRA 21-1 level.  In c-stage I NSCLC, tumor size may not be a main cause of CYFRA 21-1 
level elevation.   
As for lymph node involvement, Satoh et al. [6] showed that the increased preoperative levels of 
CYFRA 21-1 suggested the presence of N2 disease.  Pujol et al. [2, 12] also stated that patients 
who presented lymph node involvement (N2 or N3) demonstrated higher serum CYFRA 21-1 levels, 
when compared with patients without mediastinal lymph node involvement (N0 or N1).  In our 
study, however, there were no significant differences in the serum levels of CYFRA 21-1 according 
to nodal status.  The different characteristics of the subjects might be the reason for the 
discrepancy between our results and other reports.  Our subjects consisted only of c-stage I 
patients, all of whom have no lymph node enlargement.  These findings imply that lymph node 
involvement with lymphadenopathy may tend to elevate CYFRA 21-1 levels.  This may be one of 
the reasons why the CYFRA 21-1 levels in our study did not differ significantly in different 
pathologic stage groups as opposed to other reports showing higher CYFRA 21-1 levels in more 
advanced NSCLC patients [3, 5].  Most cases diagnosed as advanced stages in our study were 
those with involved lymph nodes in normal size or those with small pulmonary metastases.   
Although many studies have shown that CYFRA 21-1 is a good marker for NSCLC for diagnosis, 
CYFRA 21-1 does not seem to be a good marker for the early detection and screening of lung 
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cancer because of its low positive rate in early stage lung cancer [3, 5].  In our study of 101 c-stage 
I NSCLC cases, there were only six cases (5.9%) with the CYFRA 21-1 serum levels higher than 
the cut-off value of 3.5 ng/ml.  Therefore, the importance of measuring CYFRA 21-1 level in early 
stage lung cancer has been unclear.  Recently, Muley et al. reported the prognostic value of 
CYFRA 21-1 level in completely resected p-stage I cases [13, 14].  The proportion of high 
CYFRA 21-1 in their study was 21.2% (30 out of 141 cases), which is higher as compared to our 
result (5.9%). We speculate that this discrepancy was due to the difference in the proportion of 
histological types.  CYFRA 21-1 is generally known to be sensitive to squamous cell carcinoma as 
compared to adenocarcinoma [3, 5, 11].  The proportion of squamous cell carcinoma and 
adenocarcinoma in Muley’s study was 38.6% (59/141) and 49% (75/141), respectively, whereas our 
study was 20.8% (21/101) and 71.3% (72/101).  The large amount of adenocarcinoma cases in our 
subjects might be the reason for the lower proportion of high CYFRA 21-1 cases.  This finding 
implies that CYFRA 21-1 might not be a good marker for detecting small adenocarcinoma.  
However, our results are very similar to Muley’s findings in terms of the significance of CYFRA 
21-1 as a prognostic predictor.  Therefore, measurement of CYFRA 21-1 in early NSCLC is useful 
and valuable as a prognostic indicator.  A meta-analysis performed by Pujol et al. [15] concerning 
the prognostic effect of serum CYFRA 21-1 levels in NSCLC at any stage showed a shorter survival 
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rate of patients with high pretreatment CYFRA 21-1 levels as compared to patients with a normal 
value, and multivariate analysis demonstrated that CYFRA 21-1 was a prognostic determinant.  
Recent presented data of randomized trials has shown an absolute survival benefit for patients with 
completely resected early stage NSCLC receiving adjuvant chemotherapy as compared to 
observation alone [16-18].  CYFRA 21-1, a prognostic factor which is easily assessable 
preoperatively using a commercial kit, is considered to be very useful in developing a treatment 
plan for c-stage I NSCLC patients and might be used as an indicator to select a subset which has the 
potential for better prognosis with additional systemic chemotherapy, either preoperatively or 
postoperatively.  In addition, many molecular markers such as p53, K-ras, and erbB-2 have been 
investigated in resected specimens, and some were shown to be significant prognostic factors for 
early stage NSCLC [19, 20].  Further studies on CYFRA 21-1 in combination with these molecular 
markers might establish helpful and reliable guidance for developing treatment plans that provide 
more favorable outcomes for early stage NSCLC patients.  
In conclusion, we have demonstrated the prognostic value of preoperative CYFRA 21-1 levels in 
identifying cases with poor prognosis among c-stage I NSCLC.  Preoperative factors that can 
predict prognosis are very useful in planning a treatment for lung cancer.  The high-risk c-stage I 
NSCLC patients identified by elevated CYFRA 21-1 level may need further evaluation and require 
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multi-modality treatment for better postoperative survival. 
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Table 1. Patient Characteristics 
Categories No. of Patients 
All patients 101  
Sex 
  Male 61  
  Female 40  
Age  
  < 65 years old 45  
  ≥ 65 years old 56  
CYFRA 21-1 
  < 3.5 ng/ml 95 
  ≥ 3.5 ng/ml 6 
Histological type 
  Adenocarcinoma 72 
  Squamous cell carcinoma 21 
  Large cell carcinoma 7 
  Mucoepidermoid carcinoma 1 
  17 
Pathological stage 
   I 65 
   II 18 
   IIIA 8 
   IIIB 8 
   IV 2 
Surgical procedure 
   Lobectomy 97 
   Bilobectomy 4 
Median age: 67 years old, range 33 - 81 years old. 
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Table 2. Serum Levels of CYFRA 21-1 
Categories              No. of Patients CYFRA 21-1, ng/ml P Value  
 All ≥3.5 ng/ml 
All patients 101 6 1.66 ± 0.09        
Sex 
  Male 61 5 1.78 ± 0.11 0.078 
  Female 40 1 1.47 ± 0.14        
Age  
  < 65 years old 45 0 1.49 ± 0.10 0.092 
  ≥ 65 years old 56 6 1.79 ± 0.13        
Histological type 
  Squamous cell carcinoma 21 1 1.92 ± 0.19 0.060 
  Others 80 5 1.59 ± 0.10       
Pathological T factor 
  pT1 66 2 1.44 ± 0.10 0.0006* 
  pT2-4 35 4 2.06 ± 0.16        
Lymph node involvement 
  19 
  pN0 74 5 1.69 ± 0.11 0.491 
  pN1-2 27 1 1.56 ± 0.14        
Pathological stage 
  I 65 5 1.66 ± 0.12 0.994 
  II + III + IV 36 1 1.66 ± 0.13 
Values are shown as mean ± SE.  *P<0.05 
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Table 3. Univariate Analyses of Patient Characteristics and Survival After Surgery 
Factors No. of Patients 5-Year Survival (%) P Value 
Overall 101 81.1 
Sex 
Male 61 75.8 0.15 
Female 40 88.6 
Age 
<65 years old  45 83.5  0.61 
≥65 years old  56 78.5 
Histological type 
Squamous cell carcinoma 21 82.6 0.36 
Others 80 77.5 
CYFRA 21-1   
<3.5 ng/ml 95 84.8 0.006* 
≥3.5 ng/ml 6 50.0    
Pathological T factor  
pT1 66 89.3 0.019* 
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pT2-4 35 64.0 
Lymph node involvement 
pN0 74 88.5 0.016* 
pN1-2 27 60.0 
Pathological stage 
I 65 90.5 0.004* 
II + III + IV 36 63.2 
*P<0.05 
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Table 4. Multivariate Analyses Using the Cox Proportional Hazards Model 
Factors Relative Risk  95% CI P Value 
CYFRA 21-1 (<3.5 vs ≥3.5 ng/ml) 9.79 2.24-42.8  0.002* 
pT factor (pT1 vs pT2-4) 2.28 0.85-6.17 0.10 
pN factor (pN0 vs pN1-2) 1.68 0.41-6.83 0.47 
Pathological stage ( I vs II-IV)  3.22 0.66-15.6 0.15 
CI, confidence interval.  *P<0.05 
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Figure 1.  
The cumulative survival curves for patients with preoperatively normal serum CYFRA 21-1 level 
and patients with preoperatively high (≥3.5 ng/ml ) serum CYFRA 21-1 level.  The 5-year survival 
rate was 84.8% for normal CYFRA 21-1 patients and 50.0% for high CYFRA 21-1 patients, and the 
difference between these two groups was statistically significant (P=0.006).   
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